MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
MiNK Therapeutics, Inc. (INKT)
Company Research
Source: Yahoo! Finance
Reported EPS is $-0.16 EPS, expectations were $-0.15. INKT isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter ( see the details here Operator: Good day everyone, and welcome to the MiNK Therapeutics' Fourth Quarter 2023 Financial Results. Today's call is being recorded. All lines have been placed on mute to prevent any background noise and after the speakers' remarks, there will be a question and answer session. [Operator Instructions] I would now like to turn the conference over to Zack Armen, Head of Investor Relations. Please go ahead. Zack Armen: Thank you, Lisa, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans, and timelines, as well as timelines for data release and partnership opportunities among other
Show less
Read more
Impact Snapshot
Event Time:
INKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INKT alerts
High impacting MiNK Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INKT
News
- This MiNK Therapeutics Insider Increased Their Holding In The Last Year [Yahoo! Finance]Yahoo! Finance
- MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR [Yahoo! Finance]Yahoo! Finance
- MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACRGlobeNewswire
- MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target lowered by analysts at HC Wainwright from $10.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- MiNK Reports Fourth Quarter and Year-End 2023 Results [Yahoo! Finance]Yahoo! Finance
INKT
Earnings
- 3/21/24 - Beat
INKT
Sec Filings
- 3/21/24 - Form 10-K
- 3/21/24 - Form 8-K
- 3/5/24 - Form 4
- INKT's page on the SEC website